Charelle Carter-Brooks, MD
Urogynecology and Reconstructive Pelvic Surgery · Washington, DCNPI 1962793604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,896 of the $6,729 with a category attached, or 87.6%. 23 manufacturers reported payments, led by Axonics, Inc. at 35.3% of the total. Reporting peaked in 2022 at $2,430 and has fallen 71.8% since, to $685 in 2025.
Across 140 payments — averaging $48.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Coloplast$2K
- AbbVie$295
- Caldera Medical, Inc$275
- Integra Lifesciences Corporation$190
- Laborie Medical Technologies Corp.$168
- plus $1K from 17 others
What the payments were for
- Travel & lodging$83312%
- Food & beverage$5,89688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 54 | $2,378 |
| Coloplast | 20 | $2,264 |
| AbbVie(2 entities) | 13 | $295 |
| Caldera Medical, Inc | 8 | $275 |
| Integra Lifesciences Corporation | 2 | $190 |
| Laborie Medical Technologies Corp. | 2 | $168 |
| Acera Surgical, Inc. | 1 | $161 |
| Urovant Sciences Inc | 6 | $138 |
| Astellas Pharma US Inc | 7 | $124 |
| Hologic Sales And Service, LLC | 2 | $120 |
| Johnson & Johnson(2 entities) | 5 | $111 |
| Boston Scientific | 3 | $89 |
| Renovia Inc | 2 | $87 |
| Pfizer | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Dendreon Pharmaceuticals LLC | 2 | $42 |
| Urogen Pharma, Inc. | 2 | $38 |
| Lantheus Medical Imaging, Inc. | 1 | $36 |
| Amgen | 2 | $35 |
| 180 Medical, Inc. | 1 | $24 |
| Ambu Inc. | 1 | $23 |
| Millicent US Inc | 1 | $23 |
| Hollister Incorporated | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$1,911
- Axonics$785
- INTEGRA$521
- INTEGRA DERMAL REGENERATION TEMPLATE$174
- PRIMATRIX$174
- Restrata Wound Matrix$161
- Bulkamid$115
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 101 | $96,994 |
| MyrbetriqMirabegron | 115 | $85,667 |
| Estradiol | 190 | $13,641 |
| Trospium Chloride ErTrospium Chloride | 22 | $6,778 |
| Solifenacin Succinate | 43 | $2,589 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 67 | $2,235 |
| Trospium Chloride | 13 | $2,011 |
| Methenamine Hippurate | 12 | $1,791 |
| Clobetasol Propionate | 18 | $1,452 |
| Oxybutynin Chloride ErOxybutynin Chloride | 39 | $407 |
| Gabapentin | 12 | $137 |
| Ibuprofen | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $43 | $96,994101 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $85,667115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Washington
- Cheryl IglesiaWashington$9K
- Andrew SokolWashington$9K
- Shannon LambWashington$7K
- Lee RichterWashington$7K
- Abigail DavenportWashington$6K
- Moiuri SiddiqueWashington$4K
- Rachael SussmanWashington$3K
- Alexis DieterWashington$3K
- Helen ZhangWashington$3K
- Tatiana SansesWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.